Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Jedinak, Andrej ^a,b   Curatolo, Adam ^a   Zurakowski, David ^a   Dillon, Simon ^b,c   Bhasin, Manoj K ^b,c   Libermann, Towia A ^b,c   Roy, Roopali ^a,b   Sachdev, Monisha ^a   Loughlin, Kevin R ^b,d   Moses, Marsha A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Benign prostate hyperplasia; Non invasive biomarkers; Prostate cancer

Indexed keywords

BETA 2 MICROGLOBULIN; MUCIN 3; PEPSINOGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN PGA3; UNCLASSIFIED DRUG; PROTEOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; ADENOCARCINOMA; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; URINE;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEOME; ROC CURVE;

EID: 84929312466     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1284-z     Document Type: Article

References (50)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-907.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol. 2003;85:349-55.
4. Bosch JL, Hop WC, Kirkels WJ, Shröder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology. 1995;46(3 Suppl A):34-40.
5. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. The Urol Clin North Am. 1995;22:247-61.
6. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994;308:929-30.
7. Eckhardt MD, van Venrooij GE, van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol. 2001;166:563-8.
8. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-41.
9. Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 2012;110:287-92.
10. Mazzucchelli R, Colanzi P, Pomante R, Muzzonigro G, Montironi R. Prostate tissue and serum markers. Adv Clin Path. 2000;4:111-20.
11. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-49.
12. Catalona WJ, Richie JP, Ahmann FR, Hudson JA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol. 1994;151:1283-90.
13. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part1: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med. 1997;126:394-406.
14. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. New Eng J Med. 2009;360:1310-9.
15. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012;30:3020-5.
16. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232-41.
17. U.S. Preventive Services Task Force recommendation statement. Screening for Prostate Cancer [ http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening ].
18. Yang CC, Sun SS, Lin CY, Chuang FJ, Kao CH. Differentiation of prostate cancer and benign prostatic hyperplasia: the clinical value of 201Tl SPECT a pilot study. Ann Nuc Med. 2003;17:521-4.
19. Pal RP, Maitra NU, Mellon JK, Khan MA. Defining prostate cancer risk before prostate biopsy. Urol Oncol. 2013;31:1408-18.
20. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:12-9.
21. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395-9.
22. Afkarian M, Bhasin M, Dillon ST, Guerrero MC, Nelson RG, Knowler WC, et al. Optimizing a proteomics platform for urine biomarker discovery. Mol Cell Proteomics. 2010;9:2195-204.
23. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics. 2007;6:1638-55.
24. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008;14:6610-7.
25. Lin CY, Chin CH, Wu HH, Chen SH, Ho CW, Ko MT. Hubba: hub objects analyzer a framework of interactome hubs identification for network biology. Nucleic Acids Res. 2008;36:W438-43.
26. Faraggi D, Reiser B. Estimation of the area under the ROC curve. Stat Med. 2002;21:3093-106.
27. Zurakowski D, Johnson VM, Lee EY. Biostatistics in clinical decision making for cardiothoracic radiologists. J Thorac Imaging. 2013;28:368-75.
28. DeLong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-45.
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067-72.
30. Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colás E, et al. The present and future of prostate cancer urine biomarkers. Int J Mol Sci. 2013;14:12620-49.
31. Roy R, Coticchia CC, Yang J, Moses MA. Biomarkers in Cancer Biology. In: Vidaya V, Bonventre J, editors. Biomarkers of Toxicity: A New Era in Medicine. New York: John Wiley and Sons; 2010. p. 355-80.
32. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients. J Cancer. 2014;5:103-14.
33. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45-60.
34. Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem. 2003;278:3386-894.
35. Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J. 2004;382:363-73.
36. Arul GS, Moorghen M, Myerscough N, et al. Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut. 2000;47:753-61.
37. Wang RQ, Fang DC. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol. 2003;56:378-84.
38. Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005;18:1295-304.
39. Duncan TJ, Watson NF, Al-Attar AH, et al. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol. 2007;5:31.
40. Gritti I, Banfi G, Roi GS. Pepsinogens: physiology, pharmacology athophysiology and exercise. Pharmacol Res. 2000;41:265-81.
41. Westerveld BD, Pals G, Lamers CB, et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer. 1987;59:952-8.
42. Ichinose M, Miki K, Wong RN, et al. Methylation and expression of human pepsinogen genes in normal tissues and their alteration in stomach cancer. Jpn J Cancer Res. 1991;82:686-92.
43. Tani Y, Akiyama Y, Fukamachi H, et al. Transcription factor SOX2 up-regulates stomach-specific pepsinogen A gene expression. J Cancer Res Clin Oncol. 2007;133:263-9.
44. Teasdale C, Mander AM, Fifield R, et al. Serum beta2-microglobulin in controls and cancer patients. Clin Chim Acta. 1977;78:135-43.
45. Hemmingsen L, Skaarup P. Urinary excretion of ten plasma proteins in patients with renal carcinoma. Scan J Urol Nephrol. 1977;11:41-6.
46. Shuster J, Gold P, Poulik MD. beta 2-microglogulin levels in cancerous and other disease states. Clin Chim Acta. 1976;67:307-13.
47. Ward DG, Nyangoma S, Joy H, et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 2008;6:19.
48. Yang J, Qian J, Wezeman M, et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10:295-307.
49. Abdul M, Hoosein N. Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol. 2000;5:168-72.
50. Gross M, Top I, Laux I, et al. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007;13:1979-86.